Comparison · NCT02914275-sae
Seqirus QIV vs Comparator QIV: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Seqirus QIV vs Comparator QIV: serious adverse events. Trial comparisons, record NCT02914275-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02914275-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00658 | 0.00368 | 0.0117 | wilson | |
| Risk in group 2 | 0.00537 | 0.00183 | 0.0157 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00121 | -0.00948 | 0.00747 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.343 | 4.38 | log | |
| Odds ratio, group 1 over group 2 | 1.23 | 0.341 | 4.41 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Seqirus QIV than on Comparator QIV | 828 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Seqirus QIV | Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine. | 11 | 1,673 | EG000 |
| Group 2 | Comparator QIV | Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine. | 3 | 559 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Non-serious unsolicited AEs and serious AEs were collected from Day 1 through Day 180
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
- NCT number
- NCT02914275
- Phases
- PHASE3
- Conditions
- Influenza, Human
- Interventions
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Lead sponsor
- Seqirus
- Results first posted
- 2019-01-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02914275?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02914275-sae